AE Management of IO/TKI and Future of nccRCC

EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell

EP: 2.Challenges in Treating RCC From Community and Academic Settings

EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice

EP: 5.nccRCC: Alternative Therapies

EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC

Now Viewing

EP: 7.AE Management of IO/TKI and Future of nccRCC

EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy

EP: 9.NCCN Guideline Updates in Clear-Cell RCC

EP: 10.Best Treatment Selection in Clear-Cell RCC

Video content above is prompted by the following:

• What are the most significant adverse effects seen with TKIs and IOs?
  • How do you manage, monitor, and mitigate AEs seen with TKIs/IOS?

What education do you provide patients to ensure they understand their recommended treatment regimens and potential adverse effects with of these frontline agents?

• What pipeline therapies are you most excited about for the treatment of nccRCC?